Main Findings

• Adverse Events were reported to Pfizer during a 90-day period, following the December 1, 2020, public rollout of its COVID-19 experimental “vaccine” product.

• In the Pfizer 5.3.6 document, these AEs were categorized by System Organ Classes (SOC), in other words, by systems in the body.

Dermatological Adverse Events of Special Interest

This SOC consists of 20 dermatological adverse events. It contains two separate diagnoses: 13 erythema multiforme, a distinctive hypersensitivity reaction with target-like lesions involving the skin and mucous membranes, and seven chilblains, a localized form of vasculitis affecting mainly fingers and toes.

It is unclear why Pfizer chose not to include erythema multiforme in the Immune-Mediated/Autoimmune AESI category, which had over 500 hypersensitivity adverse events. Similarly, chilblains were not reported under the “Vasculitis category” of adverse events.

There were 20 total cases. Eighteen of the adverse events occurred in adults and just one in the elderly age group. Age was not provided on the remaining case. Seventeen (94%) of the individuals were female, one was male, and one was of unknown sex.

Emerging Patterns

The two remarkable features of this small group of patients are the overwhelming ratio of female to male and the occurrence in nonelderly adults. This has been a consistent pattern of adverse events reported in Table 7 of the 5.3.6 Pfizer document.

Time From Injection to Symptom Onset

The median onset was three days after the injection, ranging from under 24 hours to 17 days. Outcomes reported included seven “resolved/resolving”, eight “not resolved”, and six “unknown”.*

Although this Dermatological category is small in numbers, sixteen (80%) of the adverse events were categorized as serious. According to the FDA link below, serious adverse events include, but are not limited to, patient outcomes such as death, life-threatening events, hospitalizations, and disability or permanent damage.

Source: FDA: What Is a Serious Adverse Event?

Pfizer’s Conclusion

Despite an 80% “serious” adverse event rate, Pfizer concludes:

“This cumulative case review does not raise new safety issues. Surveillance will continue.”

Post-Marketing Team’s Conclusion

RECALL this unsafe “vaccine.”

Reference Information

5.3.6 AE Reporting Period

“Since the first temporary authorization for emergency supply under Regulation 174 in the UK (01 December 2020) and through 28 February 2021.”

5.3.6 AE Cases/Events

Abbreviations

• 5.3.6: Pfizer source document

• SOC: System Organ Class

• AE: Adverse Event

• AESI: Adverse Event of Special Interest

• EUA: Emergency Use Authorization by FDA

• PM: Post-Marketing

• BNT162b2: Pfizer’s mRNA COVID-19 vaccine

• Sequelae: An abnormal condition resulting from a previous disease, injury, or other trauma

Age Groups Defined in 5.3.6 (p. 25 footnote)